OvuGel 欧州連合 - ルーマニア語 - EMA (European Medicines Agency)

ovugel

vetoquinol - triptorelin acetate - hormoni hipofizari și hipotalamici și analogi - pigs (sows for reproduction) - for the synchronisation of ovulation in weaned sows to enable a single fixed-time artificial insemination.

Skysona 欧州連合 - ルーマニア語 - EMA (European Medicines Agency)

skysona

bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - alte medicamente pentru sistemul nervos - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.

Fingolimod Mylan 欧州連合 - ルーマニア語 - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod clorhidrat de - scleroză multiplă, scleroză multiplă recurent-remisivă - imunosupresoare - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 și 5. 1)orpatients cu evoluție rapidă severă scleroză multiplă recurentă remisivă definită prin 2 sau mai multe recidive care produc invaliditate într-un an și cu 1 sau mai multe leziuni evidențiate cu gadoliniu la irm craniană sau o creștere semnificativă a încărcării leziunilor t2 comparativ cu o irm anterioară recentă.

Fingolimod Mylan 欧州連合 - ルーマニア語 - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod clorhidrat de - scleroză multiplă, scleroză multiplă recurent-remisivă - imunosupresoare - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 și 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Vyvgart 欧州連合 - ルーマニア語 - EMA (European Medicines Agency)

vyvgart

argenx - efgartigimod alfa - myasthenia gravis - imunosupresoare - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Tyruko 欧州連合 - ルーマニア語 - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresoare - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 și 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.